These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

504 related items for PubMed ID: 15781326

  • 1. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
    Jani M, Tordai H, Trexler M, Bányai L, Patthy L.
    Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
    [Abstract] [Full Text] [Related]

  • 2. Suppression of membrane-type 1 matrix metalloproteinase (MMP)-mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes.
    Nakada M, Yamada A, Takino T, Miyamori H, Takahashi T, Yamashita J, Sato H.
    Cancer Res; 2001 Dec 15; 61(24):8896-902. PubMed ID: 11751414
    [Abstract] [Full Text] [Related]

  • 3. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor.
    Nar H, Werle K, Bauer MM, Dollinger H, Jung B.
    J Mol Biol; 2001 Sep 28; 312(4):743-51. PubMed ID: 11575929
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y.
    J Med Chem; 1998 Apr 09; 41(8):1209-17. PubMed ID: 9548812
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Chen L, Dunaway CM, Gu F, Mieling GE.
    J Med Chem; 1999 Jan 14; 42(1):87-94. PubMed ID: 9888835
    [Abstract] [Full Text] [Related]

  • 6. Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure.
    Lang R, Kocourek A, Braun M, Tschesche H, Huber R, Bode W, Maskos K.
    J Mol Biol; 2001 Sep 28; 312(4):731-42. PubMed ID: 11575928
    [Abstract] [Full Text] [Related]

  • 7. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T, Martinelli A, Nuti E, Carelli P, Balzano F, Uccello-Barretta G, Murphy G, Rossello A.
    Bioorg Med Chem; 2006 Jun 15; 14(12):4260-76. PubMed ID: 16483784
    [Abstract] [Full Text] [Related]

  • 8. Contributions of the MMP-2 collagen binding domain to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides.
    Xu X, Wang Y, Lauer-Fields JL, Fields GB, Steffensen B.
    Matrix Biol; 2004 Jun 15; 23(3):171-81. PubMed ID: 15296945
    [Abstract] [Full Text] [Related]

  • 9. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
    Kiyama R, Tamura Y, Watanabe F, Tsuzuki H, Ohtani M, Yodo M.
    J Med Chem; 1999 May 20; 42(10):1723-38. PubMed ID: 10346925
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
    Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E.
    Bioorg Med Chem; 2007 Jul 15; 15(14):4753-66. PubMed ID: 17512742
    [Abstract] [Full Text] [Related]

  • 11. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors.
    Kruse MN, Becker C, Lottaz D, Köhler D, Yiallouros I, Krell HW, Sterchi EE, Stöcker W.
    Biochem J; 2004 Mar 01; 378(Pt 2):383-9. PubMed ID: 14594449
    [Abstract] [Full Text] [Related]

  • 12. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
    Moy FJ, Chanda PK, Chen JM, Cosmi S, Edris W, Levin JI, Powers R.
    J Mol Biol; 2000 Sep 22; 302(3):671-89. PubMed ID: 10986126
    [Abstract] [Full Text] [Related]

  • 13. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
    Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V.
    Biochimie; 2005 Sep 22; 87(3-4):393-402. PubMed ID: 15781327
    [Abstract] [Full Text] [Related]

  • 14. Structure-function studies on inhibitory activity of Bungarus multicinctus protease inhibitor-like protein on matrix metalloprotease-2, and invasion and migration of human neuroblastoma SK-N-SH cells.
    Chou WM, Liu WH, Chen KC, Chang LS.
    Toxicon; 2010 Sep 22; 55(2-3):353-60. PubMed ID: 19706303
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
    Esser CK, Bugianesi RL, Caldwell CG, Chapman KT, Durette PL, Girotra NN, Kopka IE, Lanza TJ, Levorse DA, MacCoss M, Owens KA, Ponpipom MM, Simeone JP, Harrison RK, Niedzwiecki L, Becker JW, Marcy AI, Axel MG, Christen AJ, McDonnell J, Moore VL, Olszewski JM, Saphos C, Visco DM, Hagmann WK.
    J Med Chem; 1997 Mar 14; 40(6):1026-40. PubMed ID: 9083493
    [Abstract] [Full Text] [Related]

  • 16. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins.
    Stefanidakis M, Bjorklund M, Ihanus E, Gahmberg CG, Koivunen E.
    J Biol Chem; 2003 Sep 05; 278(36):34674-84. PubMed ID: 12824186
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA, Marques SM, Tuccinardi T, Carelli P, Panelli L, Rossello A.
    Bioorg Med Chem; 2006 Nov 15; 14(22):7539-50. PubMed ID: 16875829
    [Abstract] [Full Text] [Related]

  • 18. Direct activation of pro-matrix metalloproteinase-2 by leukolysin/membrane-type 6 matrix metalloproteinase/matrix metalloproteinase 25 at the asn(109)-Tyr bond.
    Nie J, Pei D.
    Cancer Res; 2003 Oct 15; 63(20):6758-62. PubMed ID: 14583471
    [Abstract] [Full Text] [Related]

  • 19. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.
    Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S, Tuccinardi T, Atkinson SJ, Murphy G, Balsamo A.
    Bioorg Med Chem Lett; 2005 May 02; 15(9):2311-4. PubMed ID: 15837315
    [Abstract] [Full Text] [Related]

  • 20. Crystal structure of the catalytic domain of human matrix metalloproteinase 10.
    Bertini I, Calderone V, Fragai M, Luchinat C, Mangani S, Terni B.
    J Mol Biol; 2004 Feb 20; 336(3):707-16. PubMed ID: 15095982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.